問卷

TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間:2023-09-19

張献崑
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

4Cases

2017-08-10 - 2021-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated12Sites

2021-07-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-05-02 - 2023-04-18

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2015-10-01 - 2019-12-31

Phase III

A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC) – (KEYNOTE 119)
  • Condition/Disease

    Metastatic Triple Negative Breast Cancer (mTNBC)

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
5Sites

Terminated4Sites